

## Michael Xiang

- Resident in Radiation Oncology - Radiation Therapy
- Affiliate, School of Medicine - Dean's Office

### Publications

---

#### PUBLICATIONS

- **Prognostic Factors and Treatment Patterns in the Management of Giant Cell Glioblastoma.** *World neurosurgery*  
Jin, M. C., Wu, A., Xiang, M., Azad, T. D., Soltys, S. G., Li, G., Pollom, E. L.  
2019
- **Definitive Radiotherapy with or Without Cisplatin for Cervical Cancer in Older Women**  
Xiang, M., Kidd, E.  
ELSEVIER SCIENCE INC.2019: E11
- **The Burden of Mental Health Disorders Among Elderly Patients with Gastrointestinal Malignancies**  
Harris, J., Xiang, M., Chang, D., Pollom, E.  
ELSEVIER SCIENCE INC.2019: E30–E31
- **Adjuvant treatment and survival in older women with triple negative breast cancer: A Surveillance, Epidemiology, and End Results analysis.** *The breast journal*  
Kozak, M. M., Xiang, M., Pollom, E. L., Horst, K. C.  
2019
- **National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma** *GYNECOLOGIC ONCOLOGY*  
Xiang, M., English, D. P., Kidd, E. A.  
2019; 152 (3): 599–604
- **Physiological motion of the optic chiasm and its impact on stereotactic radiosurgery dose.** *The British journal of radiology*  
Xiang, M., Chan, C., Wang, L., Jani, K., Holdsworth, S. J., Iv, M., Pollom, E., Soltys, S.  
2019: 20190170
- **National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.** *Gynecologic oncology*  
Xiang, M., English, D. P., Kidd, E. A.  
2018
- **Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis** *CANCER*  
Xiang, M., Holsinger, F., Colevas, A., Chen, M. M., Quynh-Thu Le, Beadle, B. M.  
2018; 124 (23): 4486–94
- **Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.** *Cancer*  
Xiang, M., Holsinger, F. C., Colevas, A. D., Chen, M. M., Le, Q., Beadle, B. M.  
2018
- **Comparative Effectiveness and Toxicity of Cetuximab or Cisplatin With Concurrent Radiation for Locoregionally Advanced Squamous Cell Carcinoma of The Head And Neck: A Population-Based Analysis**  
Xiang, M., Holsinger, F., Chen, M., Colevas, A., Beadle, B.  
ELSEVIER SCIENCE INC.2018: E16

- **Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent** *BLOOD*  
Xiang, M., Kim, H., Ho, V. T., Walker, S. R., Bar-Natan, M., Anahtar, M., Liu, S., Toniolo, P. A., Kroll, Y., Jones, N., Giaccone, Z. T., Heppler, L. N., Ye, et al  
2016; 128 (14): 1845-1853
- **Brachytherapy boost and cancer-specific mortality in favorable high-risk and other high-risk prostate cancer.**  
Muralidhar, V., Xiang, M. I., Orio, P. F., Martin, N. E., Beard, C., Feng, F., Hoffman, K. E., Nguyen, P. L.  
AMER SOC CLINICAL ONCOLOGY.2016
- **Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer** *JOURNAL OF CONTEMPORARY BRACHYTHERAPY*  
Muralidhar, V., Xiang, M., Orio, P. F., Martin, N. E., Beard, C. J., Feng, F. Y., Hoffman, K. E., Nguyen, P. L.  
2016; 8 (1): 1-6